Literature DB >> 20347207

Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction.

Betsy B Dokken1, W Ronald Hilwig, Mary K Teachey, R Ashish Panchal, Karl Hubner, Daniel Allen, David C Rogers, Karl B Kern.   

Abstract

AIM OF THE STUDY: Post-resuscitation syndrome leads to death in approximately 2 out of every 3 successfully resuscitated victims, and myocardial microcirculatory dysfunction is a major component of this syndrome. The aim of this study was to determine if glucagon-like peptide-1 (GLP-1) improves post-resuscitation myocardial microcirculatory function.
METHODS: Ventricular fibrillation (VF) was induced electrically in 20 anesthetized domestic swine (30-35 kg). Following 8 min of untreated VF, animals were resuscitated with aggressive advanced cardiac life support (ACLS). Animals were blindly randomized to receive a continuous infusion of either GLP-1 (10 pM/kg/min) or equal volume saline as placebo (PBO) for 4h, beginning 1 min after return of spontaneous circulation (ROSC). Left ventricular (LV) haemodynamics, LV ejection fraction, cardiac output, and coronary flow reserve (CFR) [using a standard technique of intracoronary Doppler flow measurements before and after intracoronary administration of 60 microg adenosine] were performed pre-arrest and at 1 and 4h post-resuscitation. In the present study, CFR is a measure of myocardial microcirculatory function since these swine had no obstructive coronary artery disease. Twenty-four hour post-resuscitation survival and neurological functional scores were also determined.
RESULTS: CFR was significantly increased in GLP-1-treated animals, 1h (1.79+/-0.13 in control animals vs. 2.05+/-0.12 in GLP-1-treated animals, P = <0.05) and 4h (1.82+/-0.16 in control animals vs. 2.31+/-0.13 in GLP-1-treated animals, P = <0.05) after ROSC. In addition, compared to PBO-treated animals, GLP-1 increased cardiac output 1h after ROSC (2.1+/-0.1 in control animals vs. 2.7+/-0.2 in GLP-1-treated animals, P = <0.05). There was no statistically significant difference in survival between GLP-1-treated (100%) and PBO-treated animals (78%).
CONCLUSIONS: In this swine model of prolonged VF followed by successful resuscitation, myocardial microcirculatory function was enhanced with administration of GLP-1. However, GLP-1 treatment was not associated with a clinically significant improvement in post-resuscitation myocardial function. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347207     DOI: 10.1016/j.resuscitation.2010.01.031

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  16 in total

1.  Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study.

Authors:  Roni Nielsen; Anders Jorsal; Peter Iversen; Lars Poulsen Tolbod; Kirsten Bouchelouche; Jens Sørensen; Hendrik Johannes Harms; Allan Flyvbjerg; Lise Tarnow; Caroline Kistorp; Ida Gustafsson; Hans Erik Bøtker; Henrik Wiggers
Journal:  J Nucl Cardiol       Date:  2017-08-02       Impact factor: 5.952

Review 2.  Glucagon-like peptide-1 and its cardiovascular effects.

Authors:  Kyung-Sun Heo; Keigi Fujiwara; Jun-ichi Abe
Journal:  Curr Atheroscler Rep       Date:  2012-10       Impact factor: 5.113

3.  Glycocalyx degradation leads to blood-brain barrier dysfunction and brain edema after asphyxia cardiac arrest in rats.

Authors:  Jiajia Zhu; Xing Li; Jia Yin; Yafang Hu; Yong Gu; Suyue Pan
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-21       Impact factor: 6.200

4.  DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion.

Authors:  Hui-Chun Ku; Wen-Pin Chen; Ming-Jai Su
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-07-12       Impact factor: 3.000

Review 5.  The effect of glucagon-like peptide 1 on cardiovascular risk.

Authors:  Jacob Sivertsen; Jaya Rosenmeier; Jens J Holst; Tina Vilsbøll
Journal:  Nat Rev Cardiol       Date:  2012-01-31       Impact factor: 32.419

Review 6.  Molecular and clinical roles of incretin-based drugs in patients with heart failure.

Authors:  Bassant Orabi; Rasha Kaddoura; Amr S Omar; Cornelia Carr; Abdulaziz Alkhulaifi
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

7.  Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus.

Authors:  Steven P Moberly; Kieren J Mather; Zachary C Berwick; Meredith K Owen; Adam G Goodwill; Eli D Casalini; Gary D Hutchins; Mark A Green; Yen Ng; Robert V Considine; Kevin M Perry; Robin L Chisholm; Johnathan D Tune
Journal:  Basic Res Cardiol       Date:  2013-06-14       Impact factor: 17.165

Review 8.  Cardiovascular and hemodynamic effects of glucagon-like peptide-1.

Authors:  Adam G Goodwill; Kieren J Mather; Abass M Conteh; Daniel J Sassoon; Jillian N Noblet; Johnathan D Tune
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

Review 9.  Myocardial Dysfunction and Shock after Cardiac Arrest.

Authors:  Jacob C Jentzer; Meshe D Chonde; Cameron Dezfulian
Journal:  Biomed Res Int       Date:  2015-09-02       Impact factor: 3.411

Review 10.  Coronary Microvascular Function and Beyond: The Crosstalk between Hormones, Cytokines, and Neurotransmitters.

Authors:  Carlo Dal Lin; Francesco Tona; Elena Osto
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.